{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'GB001 will be administered as an additional treatment on top of a stable standard of care (SOC)', 'regimen of mometasone furoate nasal spray (MFNS).', '4.2.2.', 'Choice of Control Group', 'All subjects will be on background SOC. The study is placebo-controlled to minimize bias', 'and provide an inactive control group to which the efficacy of GB001 can be compared.', 'Comparisons between the GB001 and placebo treatment groups will facilitate differentiation of', 'the GB001 safety profile from that of the SOC. Lastly, a placebo group, as opposed to an active', 'control, will help to understand whether the occurrence of an AE in the GB001 group is different', 'from that which would occur in this population in the absence of GB001.', '4.2.3.', 'Efficacy Endpoint Selection', 'The primary endpoint is the change from baseline to Week 16 in SNOT-22. This instrument has', 'been used in multiple clinical studies to demonstrate the impact of different types of treatment', 'interventions in subjects with CRS.', 'In addition, this study will explore the impact of GB001 on bilateral nasal polyps and associated', 'sinus symptoms, using specific assessments and questionnaires.', '4.3.', 'Justification for Dose', 'This study will assess 40 mg of GB001 in adult subjects with chronic rhinosinusitis with or', 'without bilateral nasal polyps. In a previous asthma study (PTR-36-201), GB001 5 mg and', '20 mg doses were evaluated. While both doses of GB001 were effective compared to placebo', 'in decreasing the proportion of subjects with asthma worsening/exacerbations in a treatment', 'withdrawal design, the 20 mg dose produced a larger treatment effect (20 mg: 20.8%; 5 mg:', '32.7%; placebo: 52.8%). In addition, only the 20 mg dose demonstrated statistical significance', 'for the endpoints of asthma control, Asthma Control Questionnaire (ACQ-5), and time to asthma', 'worsening relative to placebo. However, no improvements in lung function were observed,', 'suggesting that higher doses are needed to achieve clinical benefit across different endpoints,', 'including lung function. A comparable safety profile was observed across all treatment arms', '(including placebo) in this study. Considering that patients with chronic rhinosinusitis with', 'eosinophilic inflammation manifest with more inflammation and disease severity than patients', 'with asthma in general, a dose of 40 mg should be adequate and safe to investigate the efficacy', 'and safety of GB001 in this patient population. The selection of this dose encompasses the', 'totality of PK, efficacy, and safety data of GB001 available to date.', '4.4.', 'End of Study Definition', 'Subjects will be regarded to have completed the study if he/she completes the Week 16 visit.', 'The end of the study is defined as the date of the last visit of the last subject in the study.', '25', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '5.', 'STUDY POPULATION', 'Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as', 'a protocol waiver or exemption, is not permitted.', '5.1.', 'Inclusion Criteria', 'Prior to randomizing a subject, additional randomization criteria in Section 5.3 must be met.', 'Subjects are eligible to enter the Run-in period only if all of the following criteria are met:', '1. Informed Consent: Capable of giving signed informed consent which includes', 'compliance with the requirements and restrictions listed in the informed consent form', '(ICF) and in this protocol.', '2. Age: > 18 to 75 years of age at the time of Screening visit.', '3. Sex: Males or females:', 'a. Women of childbearing potential (WOCBP) must use an acceptable method of', 'contraception (see Appendix 4, Section 10.4) at least 1 month prior to screening', 'through 28 days after the last dose of IP.', '4. Diagnosis: Diagnosis of chronic rhinosinusitis with or without bilateral nasal polyps for', 'at least 12 weeks prior to Visit 1.', '5. Nasal symptoms: Presence of at least two of the following symptoms prior to Visit 1:', 'nasal plockade/obstruction/congestion', 'nasal discharge (anterior/posterior nasal drip)', 'facial pain/pressure', 'reduction or loss of smell', '6. INCS: Subjects must be on a stable administration of intranasal corticosteroids (INCS)', 'for > 2 months prior to Visit 1. For subjects using a specialized delivery device (eg,', 'XHANCETM) or corticosteroids administered via irrigation (eg, budesonide + sterile', 'saline), they must be on MFNS for > 2 weeks prior to screening.', '5.2.', 'Exclusion Criteria', 'Subjects are excluded from the study if any of the following criteria apply:', '1. Nasal symptoms: SNOT-22 score < 20 as assessed at screening.', '2. Prior polyp surgery: Subjects who have undergone any nasal surgery (excluding', 'polypectomy performed as an outpatient procedure) within 4 months before screening or', 'have had > 4 sinonasal surgeries in the past.', '3. Comorbidities: Presence of a known pre-existing clinically important condition', 'including: active tuberculosis, pulmonary fibrosis, bronchopulmonary aspergillosis,', \"eosinophilic granulomatous polyangiitis (Churg-Strauss syndrome), Young's syndrome,\", \"Kartagener's syndrome or dyskinetic ciliary syndromes, and cystic fibrosis. Clinically\", 'significant endocrine, autoimmune, metabolic, neurological, renal (calculated creatinine', '26', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}